Genomic Variation between Genetic Lines of White Leghorns Differed in Resistance to Marek’s Disease

Abstract
Genetic resistance to avian tumor virus-induced tumorigenesis and vaccine protective efficacy preventing such tumorigenicity are determined by multiple factors including host genetics, viral virulence, dose of challenge viruses, type of vaccine, vaccine dosage, and interval between vaccination and viral exposure time. Studies on human immune response to vaccination suggest host genetic variability has a strong effect and involves both genes within and outside of the major histocompatibility complex (MHC). Using chickens primarily from two highly inbred and specific pathogen free lines (63 and 72) sharing a common MHC (B*2) haplotype in challenge trials, we recently reported a striking difference in protective efficacy conveyed by HVT or CVI988/Rispens at either 500 PFU/bird or a commercial dosage. We also reported DNA methylation level that differs between the two lines of chickens at promoter regions of genes. Differential gene expression was also reported. This report documents Marek’s disease (MD) incidences of the two highly inbred lines and a series of Recombinant Congenic Strains (RCS) derived from the two lines, which were induced with a very virulent plus strain of MD virus, and illustrates genetic and epigenetic differences between the lines, which we anticipate, at least in part, are liable to the observed MD incidence and vaccine efficacy differences. The genetic and epigenetic mechanisms underlying both genetic resistances to MD and vaccine protective efficacy are complex. Therefore, continuous and systematic efforts on such study are warranted. A better understanding on genetic resistance to MD will empower the disease control through genetic or genomic selection, and a better understanding on the roles of host genetics in relation to immunogenicity in response to vaccination will serve as the touchstone for rational design and development of safer and more efficacious vaccines against infectious diseases.

Keywords: Host genetics; Genetic variation; Marek’s disease; Vaccine efficacy

Received: July 18, 2017; Accepted: August 10, 2017; Published: August 14, 2017

Abbreviations
ACUC: Animal Care and Use Committee; ADOL: Avian Disease and Oncology Laboratory; BSL-2: Biosafety Level 2; MD: Marek’s Disease; MDV: Marek’s Disease Virus; vV MDV: Very Virulent Plus MDV; MHC: Major Histocompatibility Complex; miRNA: microRNA; RCS: Recombinant Congenic Strains; SNP: Single Nucleotide Polymorphism; sRNA: Small RNA

Introduction
Marek’s disease (MD) is a α-herpesvirus-induced T-cell lymphoma in chickens [1,2]. MD historically caused devastating losses to the poultry industry worldwide but has been under control since the 1970s by wide use of vaccination [3-6]. Yet MD continues to cost the poultry industry, with an estimated revenue of over one billion dollars each year worldwide, which are incurred by the routine prevention measures and condemnation, and remains a serious threat to the poultry industry since commercial lines of chickens at large are susceptible to MD and new isolates of MD viruses (MDV) have been emerging with escalated virulence [6-12]. Therefore, current control measures using commercially available vaccines in the same routine as has been practiced during the last half century could be overwhelmed at an...
unpredicted time point in the future as it happened during the 1980s and 1990s [3,4].

Host genetic resistance is considered as an attractive approach to augment the current control measure against MD [4,13-15]. Host genetic resistance to MD was first noticed in the 1940s [16-18]. It was during and after the 1970s that researchers, using specialized experimental lines of chickens, identified and confirmed that major histocompatibility complex (MHC), the B-haplotype in chicken, significantly contributes to genetic resistance against MD [19-27]. Soon after, genes outside of the MHC were also shown to contribute to MD resistance [28,29].

Two highly inbred lines of chickens (lines 6 and 7) developed and maintained at the Avian Disease and Oncology Laboratory (ADOL) share a common MHC (B*2) haplotype, but one is highly resistant and the other is highly susceptible to MD as a result of selection [30]. Genetic resistance to MD, either due to the MHC or genes outside of the MHC, is associated with vaccine protective efficacy. Bacon and Witter in the 1990s reported that MHC B haplotypes affect host immune response to MD vaccines. Chickens with B*5 haplotype responded to serotype 2 MD vaccine better and resulted in significantly lower MD incidence than chickens with other B haplotypes. On the other hand, chickens with B*2, B*13, B*15, or B*21 haplotype(s) responded to serotype 1 MD vaccine better than to serotype 2 or 3 MD vaccine [23-26]. In recent years, we have assessed non-MHC genetic variation effect on MD vaccine efficacy using the lines 6 and 7 chickens as well as chickens from a series of recombinant congenic strains (RCS), which all have the same MHC B*2 haplotype [30]. Our data clearly showed genes outside of the MHC region significantly affect MD vaccine protective efficacy. For instance, the two progenitor lines of the RCS, lines 6 and 7, conveyed 72% and 0% protection, respectively, against a very virulent plus strain of MDV (vv+ MDV) challenge in response to HVT vaccination, while the RCS conveyed a range of 43% up to 82% against the same vv+ MDV in response to the same vaccine. Our data also showed for the first time there may be a chicken line by vaccine interaction modulating MD vaccine protective efficacy. We further hypothesized that vaccine protective efficacy, which reportedly depends on many factors, including vaccine dosage, number of vaccinations, age at vaccination, the time interval between vaccination and infection, maternal antibody, type of vaccine, and host genetics, is also partially determined by interactions among vaccine virus genome, host genome, as well as the challenging virus genome [31-33]. Based on the above findings our long-term goal is to determine what are the genetic and epigenetic differences between the genetic lines of chickens that modulate the differential protective efficacy of MD vaccines against vv+ MDV challenge when the other factors listed above are similar or identical. Earlier studies showed the primary lymphoid organ size and IgG level differ between the lines 6 and 7 [34,35]. Data from our recent collaborative studies showed that profiles of global gene expression with or without MDV challenge differ between the highly inbred line 6 and 7, and one recombinant congenic strain [36]. Using miRNA microarray, it was demonstrated that miRNAs were differentially expressed between line 6 and 7 chickens post MDV challenge [37]. DNA methylation level at the promoter region of genes was also found being different between line 6 and 7 chickens with or without MDV challenge [38-42]. The objective of this report is to document the phenotypic differences of MD incidence for the two highly inbred lines 6 and 7, and the series of RCS, to probe the genetic and epigenetic variability primarily for the lines 6 and 7, and together to elucidate the genetic and epigenetic variation between the inbred lines that may be responsible, in part, for the phenotypic differences of MD incidence and vaccine protective efficacy at macroscopic level. Our data provided additional experimental evidence in elucidating genetic and epigenetic factors that may modulate MD genetic resistance to MD and the differential immune response to MD vaccine between the genetic lines of chickens.

Materials and Methods

Experimental chickens

Specific pathogen free White Leghorns were sampled from two highly inbred lines (lines 6 and 7) and a series of 19 RCS developed and maintained at ADOL for challenge trials. Chickens from lines 6, 7, and three of the RCS series (RCS-B, RCS-M, and RCS-S) were used as the DNA source for SNP fingerprinting, and chickens from the lines 6 and 7 were used as the RNA source for small RNA sequencing. The lines 6 and 7 carry MHC B*2 haplotype [43]. The RCS were developed from the lines 6 and 7 as previously described [31,40]. Briefly, lines 6 and 7 were crossed followed by two consecutive backcrosses to the donor line 6. Each RCS was then established by sib-mating. Therefore, on average each RCS theoretically possesses 1/8 random line 6 genome and 7/8 line 6 genome [31]. All RCS share the same MHC B*2 haplotype.

Experimental layout

Each challenge trial was conducted by intraabdominally inoculating approximately 30 chicks from each selected line/RCS with a dosage of 500 plaque forming unit (PFU) of 648A passage 40 MDV on the fifth day post hatch. The challenged chicks were housed in negatively pressured BSL-2 isolators. Feed and water were supplied ad libitum. The procedures for sampling and handling of the chickens of the trials were approved by the ADOL Animal Care and Use Committee (ACUC).

Cells and viruses

Primary chicken embryo fibroblast cell cultures were used in preparation of a partially attenuated vv+ MDV, 648A passage 40 [44]. The challenge viruses used in all the challenge trials of this study were from a single batch of preparation.

Postmortem examination

Each challenge trial was terminated 8 weeks post infection. Postmortem examination was conducted for all dead and euthanized chickens to pathologically evaluate for lymphoid organ atrophy, gross tumors and peripheral nerve enlargement. Histopathology exam was employed to confirm diagnoses of MD in all cases of questionable tumors or nerve enlargements.
SNP fingerprinting

Genomic DNA samples were extracted from three chickens per line from the line 6\textsubscript{3}, line 7\textsubscript{2}, RCS-B, RCS-M, and RCS-S. The DNA samples were quantified with a Quant-iT PicoGreen dsDNA Assay (Life Technologies, Grand Island, NY). SNP typing was done with a chicken 60K SNP array [45] at DNA LandMarks Inc. (Quebec, Canada).

Small RNA profiling

Small RNA (sRNA) samples were extracted from thymus tissue of two line 6\textsubscript{3} and two line 7\textsubscript{2} chicks at 26-days of age using a miRNeasy Mini Kit (Qiagen, Valencia, CA). sRNAs were ligated to a 5’adaptor and a 3’adaptor sequentially, reverse transcription polymerase chain reaction (RT-PCR) amplified, and used directly for sequencing [46]. The sRNA sequencing was performed on an Illumina HiSeq System (San Diego, CA) by BGI USA Inc. (Woodridge, IL) [47]. sRNA sequences were analyzed following procedures described by Mehta [48] and Shu et al. [49]. Differentially expressed microRNAs were identified using the DESeq package [50].

Results

MD incidence of the line 6\textsubscript{3}, line 7\textsubscript{2}, and 19 RCS chickens induced with a partially attenuated vv+ MDV

The same vv+ MDV, 648A passage 40, induced MD in fewer than 10% of the line 6\textsubscript{3} chickens but in over 90% up to 100% of the line 7\textsubscript{2} chickens in two trials (Figure 1). Similar MD incidences for the line 6\textsubscript{3} and line 7\textsubscript{2} chickens were also observed in another trial where chickens from the two inbred lines and the 19 RCS were simultaneously challenged with the partially attenuated vv+ MDV. MD incidences for the RCS ranked from 0% (in RCS-J and RCS-L) up to 41% (RCS-M; Figure 2). Since all of the genetic lines 6\textsubscript{3}, 7\textsubscript{2}, and RCS share the same MHC, these MD incidence data clearly demonstrated that genes outside of the MHC complex significantly contribute to genetic resistance to MD.

SNP fingerprinting of line 6\textsubscript{3}, line 7\textsubscript{2}, and the three RCS

About 98% of the total 57,636 SNPs were typed successfully for all the samples. Of the successfully typed SNPs, 99.9%, 99.5%, 98.6%, 98.6%, and 99.2% were identical by state (IBS) for the lines 6\textsubscript{3}, 7\textsubscript{2}, RCS-B, RCS-M, and RCS-S, respectively. In comparison between lines, about 26.4% of the SNPs in line 7\textsubscript{2}, 6.4%, 4.0%, and 2.8% of the SNPs in RCS-B, RCS-M, and RCS-S differed from line 6\textsubscript{3}, respectively, which reside on chromosomes 1-15, 17-28 and Z. A Heat map and Dendrogram depicted the relative distance among the lines. The line 6\textsubscript{3} is clearly most distant from the line 7\textsubscript{2}, followed by RCS-B, RCS-M, and RCS-S (Figure 3). The SNP fingerprint results clearly demonstrated the very existence of genetic variation at the DNA level between the progenitor lines, and even between the progenitor background line 6\textsubscript{3} and the RCS.

Preliminary profiling of sRNA expression in thymus tissues of line 6\textsubscript{3} and 7\textsubscript{2} chicks at 26 days of age

Deep sequencing identified over a million unique sRNA for each of the chicks from both lines 6\textsubscript{3} and 7\textsubscript{2} when all reads were aligned against databases including mirBase (Release 18, Nov. 2011), rRNA etc. (Rfam10.1, NCBI GenBank), mRNA, Target, Repeat (http://hgdownload.cse.ucsc.edu/goldenPath/galGal3/bigZips/chromOut.tar.gz), and Genome (http://hgdownload.cse.ucsc.edu/goldenPath/galGal3/bigZips/chromFa.tar.gz). Only about 11.3% of sRNAs were found in common between line 6\textsubscript{3} chicks and 13.9% of sRNAs between line 7\textsubscript{2} chicks (Figure 4). High percentages of sRNAs differed between line 6\textsubscript{3} and line 7\textsubscript{2} chicks, which ranged from 42% versus 45% (line 6\textsubscript{3} bird 1 versus line 7\textsubscript{2}}
bird 2) to 33% versus 55% (line 6, bird 1 versus line 7, bird 1) (Figure 5). The preliminary analysis of the sRNA data indicated that small non-coding RNAs differ in expression in the chickens within and between the highly inbred lines 6, and 7.

Discussion

It is common knowledge to the poultry research community and the industry that vaccination is of vital importance to protect poultry against MD that once devastated and still remains a serious threat to the industry worldwide [3]. It is also hard to imagine that the poultry industry could have enjoyed the success and prosperity as it has been during the last 40 years without the invention and proper implementation of varied vaccines to efficiently control a variety of infectious diseases of poultry [51,52]. By the same token, it holds pretty much true, if not more true, in human medicine as well [53]. Yet the challenge for maintaining such a good level of control and even tougher a challenge for improving the control against infectious diseases remains. Many factors affect genetic resistance to MD and vaccine protective efficacy. Some of these have been well investigated and reported [23-26,54-56]. We recently showed non-MHC genetic variation, in addition to MHC haplotype that was primarily reported by Bacon and Witter in the 1990s [23-26,57], also plays an important role in modulating MD vaccine efficacy [31-33]. The findings of MHC and non-MHC effects on MD vaccine protective efficacy are in good agreement with reports of studies both in humans and other animals [58,59]. Line 6 is resistant to MD while line 7 is highly susceptible to MD.

Figures 1 and 2 documented the striking difference in MD incidence between the two genetic lines of chickens challenged with a partially attenuated vv+ MDV, 648A passage 40, in three consecutive trials. The striking difference was also observed in HVT protective efficacy between the two lines of chickens. Under a commercial dosage, two HVT vaccines (from two different manufacturers) conveyed protection well over 80% for line 6 chickens challenged with low passage vv+ MDV while the same two HVT vaccines provided 0% and 10% protection, respectively, in line 7 chickens under the same challenge [32]. Evidently, host genetic resistance to MD is highly and positively associated with HVT protective efficacy. Furthermore, genetic and epigenetic differences that exist between the two inbred lines of chickens may underlie not only genetic resistance to MD but also host
genetics effect on vaccine protective efficacy. The exact genetic and epigenetic factors that confer genetic resistance and/or vaccine efficacy remain to be investigated in addition to what have been reported [60]. SNP-fingerprinting showed that line 6 differs at the DNA level from line 7. The same SNP-fingerprint showed three RCS (RCS-B, RCS-M, and RCS-S) were more different from line 7 than line 6, as expected (Figure 3). Our recent study on gene expression profiling indicated that global gene expressions were significantly different between the chickens of lines 6 and 7, as well as expected [36]. In addition to genetic differences, epigenetic differences now have been found to commonly exist between the two lines of chickens. A significant portion of genes that have been assessed differ in DNA methylation level at CpG sites within the CpG islands of promoter regions between the line 6 and 7 chickens [38-42]. Difference in microRNA expression was also detected using chicken microRNA array between the two lines of chickens [37]. The results of preliminary analyses of small RNA data acquired from Illumina’s HiSeq deep sequencing in this study, which include microRNAs, suggested there is abundant variability within as well as between line 6 and 7 chickens (Figures 4 and 5). This finding is in good agreement with our earlier report [37]. The differences in epigenetic factors, DNA methylation, histone modification [61], and small RNA expression potentiated the possibility that the underlying mechanism conferring resistance to MD and host effect on vaccine protective efficacy may be pretty complex and potentially involving all or a different combination of the factors that differ between the two genetic lines. This may very well hold true, more or less, in human medicine with regard to disease resistance and immune response to vaccination at the personal medicine level.

In summary, we propose that host genetic resistance to MD and host genetics effect on vaccine protective efficacy are highly likely determined by genetic and epigenetic factors jointly. The genetic factors include genomic DNA polymorphisms (SNPs, deletions, and insertions, translocations) and gene expression; epigenetic factors include DNA methylation, histone modification, and non-coding (long and small) RNA expression. Both genetic and epigenetic factors likely encompass MHC and non-MHC genomic regions. The line 6 and 7 chickens are an important genetic resource for poultry research, which should be instrumental not only for identifying genes, pathways, and specific epigenetic factors underlying genetic resistance to MD, but also to host genetics effect on vaccine protective efficacy. Identification of specific genes, pathways, and epigenetic factors affecting genetic resistance and vaccine protective efficacy is of great importance for sustaining current control of the infectious disease and for development of new and more efficacious vaccine, which could continue to empower the poultry industry to maintain good control of the disease and to provide quality chicken products for consumers.

Acknowledgements

This work was partially supported by an USDA-NRICGP grant 2008-35204-04660 (awarded to J.S. & H.Z.) and by funds from National Research Sponsored Project-8 (NRSP-8).

References

1. Osterrieder N, Kamal JP, Schumacher D, Tischer BK, Trapp S (2006) Marek’s disease virus: from miasma to model. Nat Rev Microbiol 4: 283-294.
2. Witter RL (2005) Marek’s disease: the continuing struggle between pathogen and host. Vet J 170: 149-150.
3. Biggs PM, Nair V (2012) The long view: 40 years of Marek’s disease research and Avian Pathology. Avian Pathol 41: 3-9.
4. Gimeno IM (2008) Marek’s disease vaccines: a solution for today but a worry for tomorrow? Vaccine 26: C31-C41.
5. Baigent SJ, Smith LP, Nair VK, Currie RJ (2006) Vaccinal control of Marek’s disease: current challenges, and future strategies to maximize protection. Vet Immunol Immunopathol 112: 78-86.
6. https://www.ars.usda.gov/there-was-a-problem/?asperrorpath=/research/publications/publication/
7. Purchase HG (1985) Clinical disease and its economic impact. In: Payne LN (ed.) Marek’s Disease, Scientific Basis and Methods of Control, Boston, USA: Martinus Nijhoff Publishing.
8. Bacon LD, Hunt HD, Cheng HH (2011) Genome-wide identification and quantification of cis- and trans-regulated genes responding to Marek’s disease virus infection via analysis of allele-specific expression. Front Genet 2: 113.
9. Abdul-Careem MF, Hunter BD, Sarson AJ, Parvizi P, Haghighi HR, et al. (2008) Host responses are induced in feathers of chickens infected with Marek’s disease virus. Virology 370: 323-332.
10. Schat KA, Baranowski E (2007) Animal vaccination and the evolution of viral pathogens. Rev Sci Tech 26: 327-338.
11. Nair V (2005) Evolution of Marek’s disease-a paradigm for incessant race between the pathogen and the host. Vet J 170: 175-183.
12. Davison F, Nair V (2005) Use of Marek’s disease vaccines: could they be driving the virus to increasing virulence? Expert Rev Vaccines 4: 77-88.
13. Maceachern S, Muir WM, Crosby SD, Cheng HH (2011) Genomewide identification and quantification of cis- and trans-regulated genes responding to Marek’s disease virus infection via analysis of allele-specific expression. Front Genet 2: 113.
14. Abdul-Careem MF, Hunter BD, Sarson AJ, Parvizi P, Haghighi HR, et al. (2008) Host responses are induced in feathers of chickens infected with Marek’s disease virus. Virology 370: 323-332.
15. Cheng H, Niikura M, Kim T, Mao W, MacLea KS, et al. (2008) Using integrative genomics to elucidate genetic resistance to Marek’s disease in chickens. Dev Biol (Basel) 132: 365-372.
16. Biggs PM (1973) Marek’s disease. In: Kaplan AS (ed.) The Herpesviruses. New York and London: Academic Press.
17. Davison F, Nair V (2004) Marek’s disease- an evolving problem. Oxford: Elsevier Academic Press.
18. Cole RK (1968) Studies on genetic resistance to Marek’s disease. Avian Dis 12: 9-28.
19. Briles WE, Briles RW, Pollock DL, Pattison M (1982) Marek’s disease resistance of B (MHC) heterozygotes in a cross of purebred Leghorn lines. Poul Sci 61: 205-211.
20 Schat KA, Taylor RL, Briles WE (1994) Resistance to Marek's disease in chickens with recombinant haplotypes to the major histocompatibility (B) complex. Poult Sci 73: 502-508.

21 Bacon LD, Witter RL, Crittenden LB, Fadly A, Motta J (1981) B-haplotype influence on Marek's disease, Rous sarcoma, and lymphoid leukemia virus-induced tumors in chickens. Poult Sci 60: 1132-1139.

22 Briles WE, Stone HA, Cole RK (1977) Marek's disease: effects of B histocompatibility alloalleles in resistant and susceptible chicken lines. Science 195: 193-195.

23 Bacon LD, Witter RL (1992) Influence of turkey herpesvirus vaccination on the B-haplotype effect on Marek's disease resistance in 15. B congenic chickens. Avian Dis 36: 378-385.

24 Bacon LD, Witter RL (1993) Influence of B-haplotype on the relative efficacy of Marek's disease vaccines of different serotypes. Avian Dis 37: 53-59.

25 Bacon LD, Witter RL (1994) B haplotype influence on the relative efficacy of Marek's disease vaccines in commercial chickens. Poult Sci 73: 481-487.

26 Bacon LD, Witter RL (1994) Serotype specificity of B-haplotype influence on the relative efficacy of Marek's disease vaccines. Avian Dis 38: 65-71.

27 Omar AR, Schat KA (1996) Syngeneic Marek's disease virus (MDV)-specific cell-mediated immune responses against immediate early, late, and unique MDV proteins. Virology 222: 87-99.

28 Witter RL, Bacon LD, Hunt HD, Cheng HH (1994) Genetics and vaccines for the future control of Marek's disease.

29 Liu HC, Kung Hj, Fulton JE, Morgan RW, Cheng HH (2001) Growth hormone interacts with the Marek's disease virus SORF2 protein and is associated with disease resistance in chicken. Proc Natl Acad Sci USA 98: 9203-9208.

30 Bacon LD, Motta J, Cheng H, Vallejo R, Witter R (1996) Use of recombinant congenic chicken strains to define non-HMC genes influencing Marek's disease susceptibility. In: Silva RF, Cheng HH, Coussens PM, Lee LF, Velicer LF (eds.) Current Research on Marek's Disease. American Association of Avian Pathologists, Inc. pp: 63-68.

31 Chang S, Dunn JR, Heidari M, Lee LF, Song J, et al. (2010) Genetics and vaccine efficacy: host genetic variation affecting Marek's disease vaccine efficacy in White Leghorn chickens. Poult Sci 89: 2083-2091.

32 Chang S, Dunn JR, Heidari M, Lee LF, Ernst C, et al. (2012) Vaccine by chicken line interaction alters the protective efficacy against challenge with a very virulent plus strain of Marek's disease virus in White Leghorn chickens. World Journal of Vaccines 2: 1-11.

33 Chang S, Ding Z, Dunn JR, Lee LF, Heidari M, et al. (2011) A comparative evaluation of the protective efficacy of rMD5deltaMeq and CVI988/ Rispens against a vv+ strain of Marek's disease virus infection in a series of recombinant congenic strains of White Leghorn chickens. Avian Dis 55: 384-390.

34 Zhang HM, Hunt HD, Kulkarni GB, Palmquist DE, Bacon LD, et al. (2006) Lymphoid organ size varies among inbred lines 6(3) and 7(2) and their thirteen recombinant congenic strains of chickens with the same major histocompatibility complex. Poult Sci 85: 844-853.

35 Yonash N, Bacon LD, Smith EJ (2002) Concentration of immunoglobulin G in plasma varies among 6C7 recombinant congenic strains of chickens. Poult Sci 81: 1104-1108.

36 Yu Y, Luo J, Mitra A, Chang S, Tian F, et al. (2011) Temporal transcriptome changes induced by MDV in Marek's disease-resistant and -susceptible inbred chickens. BMC Genomics 12: 501.

37 Tian F, Luo J, Zhang H, Chang S, Song J, et al. (2012) miRNA expression signatures induced by Marek's disease virus infection in chickens. Genomics 99: 152-159.

38 Luo J, Yu Y, Chang S, Tian F, Zhang H, et al. (2012). DNA Methylation Fluctuation Induced by Virus Infection Differs between MD-resistant and -susceptible Chickens. Front Genet 3: 20.

39 Luo J, Yu Y, Zhang H, Tian F, Chang S, Cheng HH, et al. (2011) Down-regulation of promoter methylation level of CD4 gene after MDV infection in MD-susceptible chicken line. BMC Proc 4: 57.

40 Yu Y, Zhang H, Byerly MS, Bacon LD, Porter TE, et al. (2009) Alternative splicing variants and DNA methylation status of BDNF in inbred chicken lines. Brain Res 1269: 1-10.

41 Yu Y, Zhang H, Tian F, Zhang W, Fang H, et al. (2008) An integrated epigenetic and genetic analysis of DNA methyltransferase genes (DNMTs) in tumor resistant and susceptible chicken lines. PLoS ONE 3: e2672.

42 Yu Y, Zhang H, Tian F, Bacon L, Zhang Y, et al. (2008) Quantitative evaluation of DNA methylation patterns for ALVE and TVB genes in a neoplastic disease susceptible and resistant chicken model. PLoS ONE 3: e1731.

43 Bacon LD, Hunt HD, Cheng HH (2000). A review of the development of chicken lines to resolve genes determining resistance to diseases. Poult Sci 79: 1082-1093.

44 Witter RL, Cailnek BW, Buscaglia C, Gimenos IM, Schat KA, et al. (2005) Classification of Marek's disease viruses according to pathotype: philosophy and methodology. Avian Pathol 34: 75-90.

45 Groenen MA, Megens HJ, Zare Y, Warren WC, Hillier LW, et al. (2011) The development and characterization of a 60K SNP chip for chicken. BMC Genomics 12: 274.

46 Lai NC, Lim LP, Weinstein EG, Bartel DP (2001) An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans. Science 294: 858-862.

47 BG (2017) BG small ma sequencing-a service overview.

48 Mehta JP (2014) Sequencing small RNA: introduction and data analysis fundamentals. Methods Mol Biol 1182: 93-103.

49 Shu Y, Liu Y, Li W, Song L, Zhang J, et al. (2016) Genome-wide investigation of MicroRNAs and their targets in response to freezing stress in Medicago sativa L., based on high-throughput sequencing G3. Bethesda 6: 755-765.

50 Anders S, Huber W (2010) Differential expression analysis for sequence count data. Genome Biol 11: R106.

51 Kumar S, Koul M, Rai A (2010) Role of immunostimulatory molecules in poultry vaccines. Recent Pat Biotechnol 4: 235-241.

52 Safi YM, Fadly AM, Glisson JR, McDougald LR, Nolan LK, et al. (2008) Diseases of poultry. Wiley-Blackwell, NJ, USA.

53 Tan TQ (2010) Serious and invasive pediatric pneumococcal disease: epidemiology and vaccine impact in the USA. Expert Rev Anti Infect Ther 8: 117-125.

54 Heine HG, Foord AJ, Young PL, Hooper PT, Lehrbach PR, et al. (1997) Recombinant fowlpox virus vaccines against Australian virulent Marek's disease virus: gene sequence analysis and comparison of vaccine efficacy in specific pathogen free and production chickens. Virus Res 50: 23-33.
55 Witter RL (1997) Increased virulence of Marek’s disease virus field isolates. Avian Dis 41: 149-163.

56 Islam AF, Walkden-Brown SW, Groves PJ, Underwood GJ (2007) Effects of vaccine dose, virus challenge dose and interval from vaccination to challenge on protection of broiler chickens against Marek’s disease virus challenge. Aust Vet J 85: 348-355.

57 Bacon LD, Witter RL (1995) Efficacy of Marek’s disease vaccines in Mhc heterozygous chickens: Mhc congenic x inbred line F1 matings. J Hered 86: 269-273.

58 Hohler T, Reuss E, Evers N, Dietrich E, Rittner C, et al. (2002) Differential genetic determination of immune responsiveness to hepatitis B surface antigen and to hepatitis A virus: a vaccination study in twins. Lancet 360: 991-995.

59 Glass EJ (2004) Genetic variation and responses to vaccines. Anim Health Res Rev 5: 197-208.

60 Dong K, Chang S, Xie Q, Black-Pyrkosz A, Zhang H, et al. (2017) Comparative transcriptomics of genetically divergent lines of chickens in response to Marek’s disease virus challenge at cytolytic phase. PLoS ONE 12: e0178923.

61 Luo J, Mitra A, Tian F, Chang S, Zhang HM, et al. (2012) Histone Methylation Analysis and Pathway Predictions in Chickens after MDV Infection. PLoS ONE 7: e41849.